Sugi Predict

Sugi Predict / Compounds / SCHEMBL2939797

SCHEMBL2939797

SCHEMBL2939797

Cc1cnc2ccccc2c1CN1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)C12CC2

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.58
▸ EGLN2 Q96KS0 5/20 0.34
▸ EGLN1 Q9GZT9 5/20 0.34
▸ EGLN3 Q9H6Z9 5/20 0.34
▸ KDM4A O75164 1/20 0.34
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ TAS2R8 Q9NYW2 3/20 0.33
▸ MCHR1 Q99705 3/20 0.32
▸ KCNH2 Q12809 3/20 0.32
▸ XIAP P98170 2/20 0.32
▸ EBP Q15125 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932627 0.90 IGF1R (0.56) IGF1RPTGDR2TAS2R8MCHR1KCNH2
SCHEMBL2937902 0.90 IGF1R (0.56) IGF1RPTGDR2TAS2R8MCHR1KCNH2
SCHEMBL2994785 0.90 IGF1R (0.56) IGF1RPTGDR2TAS2R8MCHR1KCNH2
SCHEMBL2937353 0.89 IGF1R (0.73) IGF1RTAS2R8
SCHEMBL2939362 0.89 IGF1R (0.56) IGF1RPTGDR2TAS2R8MCHR1KCNH2
SCHEMBL2934492 0.89 IGF1R (0.56) IGF1RTAS2R8MCHR1XIAP
SCHEMBL2937384 0.89 IGF1R (0.56) IGF1RPTGDR2TAS2R8MCHR1KCNH2
SCHEMBL2943165 0.86 IGF1R (0.52) IGF1RMCHR1KCNH2LMNAMAPK1
SCHEMBL2941272 0.85 IGF1R (0.45) IGF1R
SCHEMBL2936711 0.85 GCGR (0.42) IGF1RTAS2R8MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885EGLN2 2827/4885EGLN1 2859/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885EGLN2 3230/4885EGLN1 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.